Patents Assigned to TargetThera LLC
  • Patent number: 12624109
    Abstract: A chemical compound and a method for treating cancer in a mammal. The chemical compound is a first Markusch structure of A-L1-PEG1-L2-PEG2-CL-X, a second Markusch structure of A-L1-PEG1-N3, or a third Markusch structure of A-L1-PEG1-OMethyl. A-L1-PEG is a targeting structure configured for targeting av integrins in cancer cells and does not include a standard multivalent nitrogen moiety. A is a structure that includes a standard carboxylic acid moiety. L1 and L2 are linking structures. PEG1 and PEG2 are polyethylene glycol structures having n2 and n4 monomer units, respectively, where n2 is in range of 5-72, n4 is in range of 0-67, and n2+n4 is in range of 20-72. CL is a cleavage linker linked to PEG2. X is a chemotherapy linked to CL. N3 is —N?N?N. In one embodiment, the method uses the first Markusch structure to treat the cancer.
    Type: Grant
    Filed: April 25, 2023
    Date of Patent: May 12, 2026
    Assignee: TargetThera LLC
    Inventors: Shaker A. Mousa, Bruce A. Hay